Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2022; 17(01): 003-010
DOI: 10.1055/s-0042-1748789
Original Article

Risk Factors Associated with Malignant Transformation of Astrocytoma: Competing Risk Regression Analysis

Thara Tunthanathip
1   Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
,
Surasak Sangkhathat
2   Department of Surgery, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
3   Department of Biomedical Sciences, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
,
Kanet Kanjanapradit
4   Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
› Author Affiliations Funding The study was supported by the Health Systems Research Institute (Thailand; grant no. 63-078).
› Further Information
   Permissions and Reprints

Abstract

Background Malignant transformation (MT) of low-grade astrocytoma (LGA) triggers a poor prognosis in benign tumors. Currently, factors associated with MT of LGA have been inconclusive. The present study aims to explore the risk factors predicting LGA progressively differentiated to malignant astrocytoma.

Methods The study design was a retrospective cohort study of medical record reviews of patients with LGA. Using the Fire and Gray method, the competing risk regression analysis was performed to identify factors associated with MT, using both univariate and multivariable analyses. Hence, the survival curves of the cumulative incidence of MT of each covariate were constructed following the final model.

Results Ninety patients with LGA were included in the analysis, and MT was observed in 14.4% of cases in the present study. For MT, 53.8% of patients with MT transformed to glioblastoma, while 46.2% differentiated to anaplastic astrocytoma. Factors associated with MT included supratentorial tumor (subdistribution hazard ratio [SHR] 4.54, 95% confidence interval [CI] 1.08–19.10), midline shift > 1 cm (SHR 8.25, 95% CI 2.18–31.21), and nontotal resection as follows: subtotal resection (SHR 5.35, 95% CI 1.07–26.82), partial resection (SHR 10.90, 95% CI 3.13–37.90), and biopsy (SHR 11.10, 95% CI 2.88–42.52).

Conclusion MT in patients with LGA significantly changed the natural history of the disease to an unfavorable prognosis. Analysis of patients' clinical characteristics from the present study identified supratentorial LGA, a midline shift more than 1 cm, and extent of resection as risk factors associated with MT. The more extent of resection would significantly help to decrease tumor burden and MT. In addition, future molecular research efforts are warranted to explain the pathogenesis of MT.

Keywords

malignant transformation - low-grade glioma - high-grade glioma - diffuse astrocytoma

Authors' Contributions

T.T.: Concept, study design, data collection, statistical analysis, literature overview, and discussion. S.S.: Concept, study design, data collection, literature overview, and discussion. K.K.: Concept, data collection, and discussion.




Publication History

Article published online:
01 June 2022

© 2022. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Tunthanathip T, Ratanalert S, Sae-Heng S. et al. Prognostic factors and nomogram predicting survival in diffuse astrocytoma. J Neurosci Rural Pract 2020; 11 (01) 135-143
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Dong X, Noorbakhsh A, Hirshman BR. et al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neurooncol Pract 2016; 3 (01) 29-38
    PubMedGoogle Scholar
  • 3 Stupp R, Mason WP, van den Bent MJ. et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352 (10) 987-996
    CrossrefPubMedGoogle Scholar
  • 4 Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quiñones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 2010; 112 (01) 10-17
    CrossrefPubMedGoogle Scholar
  • 5 Sakarunchai I, Sangthong R, Phuenpathom N, Phukaoloun M. Free survival time of recurrence and malignant transformation and associated factors in patients with supratentorial low-grade gliomas. J Med Assoc Thai 2013; 96 (12) 1542-1549
    PubMedGoogle Scholar
  • 6 Murphy ES, Leyrer CM, Parsons M. et al. Risk factors for malignant transformation of low-grade glioma. Int J Radiat Oncol Biol Phys 2018; 100 (04) 965-971
    CrossrefPubMedGoogle Scholar
  • 7 Broniscer A, Baker SJ, West AN. et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol 2007; 25 (06) 682-689
    CrossrefPubMedGoogle Scholar
  • 8 Klein JP. Modelling competing risks in cancer studies. Stat Med 2006; 25 (06) 1015-1034
    CrossrefPubMedGoogle Scholar
  • 9 Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. Biometrics 1983; 39 (02) 499-503
    CrossrefPubMedGoogle Scholar
  • 10 Kohn MA, Senyak J. Sample Size Calculators [Internet]. Accessed May 25, 2021 at: https://sample-size.net/sample-size-survival-analysis/
    Google Scholar
  • 11 Gupta A, Dwivedi T. A simplified overview of World Health Organization classification update of central nervous system tumors 2016. J Neurosci Rural Pract 2017; 8 (04) 629-641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Tunthanathip T, Madteng S. Factors associated with the extent of resection of glioblastoma. Precis Cancer Med 2020; 3: 12
    CrossrefGoogle Scholar
  • 13 Im JH, Hong JB, Kim SH. et al. Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification. Sci Rep 2018; 8 (01) 777
    CrossrefPubMedGoogle Scholar
  • 14 Tunthanathip T, Kanjanapradit K. Glioblastoma multiforme associated with arteriovenous malformation: a case report and literature review. Ann Indian Acad Neurol 2020; 23 (01) 103-106
    CrossrefPubMedGoogle Scholar
  • 15 Schwartz LH, Litière S, de Vries E. et al. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132-137
    CrossrefPubMedGoogle Scholar
  • 16 Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
    CrossrefGoogle Scholar
  • 17 Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 2017; 36 (27) 4391-4400
    CrossrefPubMedGoogle Scholar
  • 18 Stata.com. [Internet]. Competing-risks regression. Accessed May 9, 2020 at: https://www.stata.com/features/overview/competing-risks-regression/
    Google Scholar
  • 19 Stata.com. [Internet]. stcurve-Stata. Accessed May 9, 2020 at: https://www.stata.com/manuals/ststcurve.pdf
    Google Scholar
  • 20 Tom MC, Park DYJ, Yang K. et al. Malignant transformation of molecularly classified adult low-grade glioma. Int J Radiat Oncol Biol Phys 2019; 105 (05) 1106-1112
    CrossrefPubMedGoogle Scholar
  • 21 Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB. Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 1997; 79 (02) 370-379
    CrossrefPubMedGoogle Scholar
  • 22 Wu CX, Lin GS, Lin ZX. et al. Peritumoral edema on magnetic resonance imaging predicts a poor clinical outcome in malignant glioma. Oncol Lett 2015; 10 (05) 2769-2776
    CrossrefPubMedGoogle Scholar
  • 23 Blystad I, Warntjes JBM, Smedby Ö, Lundberg P, Larsson EM, Tisell A. Quantitative MRI for analysis of peritumoral edema in malignant gliomas. PLoS One 2017; 12 (05) e0177135
    CrossrefPubMedGoogle Scholar
  • 24 Lin ZX. Glioma-related edema: new insight into molecular mechanisms and their clinical implications. Chin J Cancer 2013; 32 (01) 49-52
    CrossrefPubMedGoogle Scholar
  • 25 Kiliç T, Ozduman K, Elmaci I, Sav A, Necmettin Pamir M. Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas. J Clin Neurosci 2002; 9 (05) 549-552
    CrossrefPubMedGoogle Scholar
  • 26 Majchrzak K, Kaspera W, Bobek-Billewicz B. et al. The assessment of prognostic factors in surgical treatment of low-grade gliomas: a prospective study. Clin Neurol Neurosurg 2012; 114 (08) 1135-1144
    CrossrefPubMedGoogle Scholar
  • 27 Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62 (04) 753-764 , discussion 264–266
    Google Scholar
  • 28 Kaewborisutsakul A, Sae-Heng S. Kitsiripant, et al. The first awake craniotomy for eloquent glioblastoma in Southern Thailand. J Health Sci Med Res. 2020; 38 (01) 61-65
    Google Scholar
  • 29 Champeaux C, Houston D, Dunn L, Resche-Rigon M. Intracranial WHO grade I meningioma: a competing risk analysis of progression and disease-specific survival. Acta Neurochir (Wien) 2019; DOI: 10.1007/s00701-019-04096-9.
    CrossrefPubMedGoogle Scholar
  • 30 Lucas Jr JT, Colmer IV HG, White L. et al. Competing risk analysis of neurologic versus nonneurologic death in patients undergoing radiosurgical salvage after whole-brain radiation therapy failure: who actually dies of their brain metastases?. Int J Radiat Oncol Biol Phys 2015; 92 (05) 1008-1015
    CrossrefPubMedGoogle Scholar
  • 31 Kimura T, Ochiai C, Kawai K, Morita A, Saito N. How definitive treatment affects the rupture rate of unruptured cerebral aneurysms: a competing risk survival analysis. J Neurosurg 2019; 132 (04) 1062-1067
    CrossrefPubMedGoogle Scholar
  • 32 Singh G, Mehrotra A, Sardhara J. et al. Multiple glioblastomas: are they different from their solitary counterparts?. Asian J Neurosurg 2015; 10 (04) 266-271
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Tunthanathip T, Sangkhathat S, Tanvejsilp P, Kanjanapradit K. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas. Clin Neurol Neurosurg 2020; 195: 105891
    CrossrefPubMedGoogle Scholar
  • 34 Rotariu D, Gaivas S, Faiyad Z. et al. Malignant transformation of low grade gliomas into glioblastoma a series of 10 cases and review of the literature. Romanian Neurosurgery. 2010; 17 (04) 403-412
    Google Scholar
  • 35 Taweesomboonyat C, Tunthanathip T, Sae-Heng S, Oearsakul T. Diagnostic yield and complication of frameless stereotactic brain biopsy. J Neurosci Rural Pract 2019; 10 (01) 78-84
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Pourhoseingholi MA, Baghestani AR, Vahedi M. How to control confounding effects by statistical analysis. Gastroenterol Hepatol Bed Bench 2012; 5 (02) 79-83
    PubMedGoogle Scholar
  • 37 Tunthanathip T, Sangkhathat S. Temozolomide for patients with wild-type isocitrate dehydrogenase (IDH) 1 glioblastoma using propensity score matching. Clin Neurol Neurosurg 2020; 191: 105712
    CrossrefPubMedGoogle Scholar
  • 38 Tunthanathip T, Mamueang K, Nilbupha N, Maliwan C, Bejrananda T. No association between isocitrate dehydrogenase 1 mutation and increased survival of glioblastoma: a meta-analysis. J Pharm Negat Results 2020; 11 (01) 1-8
    CrossrefGoogle Scholar
  • 39 Park CK, Park I, Lee S. et al. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas. Oncotarget 2015; 6 (41) 43653-43666
    CrossrefPubMedGoogle Scholar